bought only one new stock and added to seven others in the first
quarter of 2012. Owens has actively managed the $22.5 billion
Vanguard Health Care Fund (VGHCX) for more than 25 years and
delivered an average annual return of 16.46% since inception in
1984. The fund offers investors low-cost exposure to the health
care industry, but the narrow scope makes it susceptible to wide
swings in performance.
The sole stock Owens bought in the first quarter is Alkermes Inc.
), and he made the largest additions to Warner Chil Plc (
) and Boston Scientific (
The fund's top holdings are Merck & Co. (
), UnitedHealth Group Inc. (
), Forest Laboratories Inc. (
), Roche Holding AG (
) and Pfizer Inc. (
"At our last writing, we asserted that 'global economic
conditions have undeniably improved.' That statement seems more
open to question now, especially in light of several recent
developments, including the U.S. debt rating downgrade and
further deterioration in the European financial framework. We
believe our investment approach is designed to capture much of
the upside in any global economic improvement. It's also
important to note that the high-quality business models that
typify dividend-growing companies should help mitigate the risks
that have become much more obvious of late."
Owens bought 787,900 shares of Alkermes Inc. (
) at an average price of near $18 in the first quarter. It now
comprises 0.07% of his portfolio. Alkermes is an integrated
biotechnology company that creates drugs to treat chronic
diseases, including Vivitrol for alcohol dependence and Risperdal
Consta for schizophrenia and bipolar I disorder.
Alkermes merged with Elan Drug Technologies (
), a unit of Ireland's Elam Corp. Plc, on Sept. 16, 2011 and
reported its first full quarter results with the combined
companies in February 2012. Alkermes posted a net loss of $14.8
million on revenues of $125.6 million, compared to $44 million
the prior year. The company's revenues are based on five key
products, including one, BYDUREON, which was launched in the EU
in the second half of calendar year 2011. Three of its products
will also face or are expected to face in the near term, generic
The company had as of Dec. 31, 2011, cash and total investments
of $234 million, compared to $294.7 million at March 31, 2011.
The amount diminished due to the use of $50 million to fund the
acquisition of Elan Drug Technologies.
Over the last 10 years, Alkermes' revenue has grown at an annual
rate of 15.5%. Free cash flow was negative $14.9 million in 2011
and negative $27.8 million in 2011. With an incalculable P/E
ratio, the company has a P/B ratio of 2.5 and P/S ratio of 12.3.
Warner Chilcott Plc (
, a leading specialty pharmaceutical company focused on women's
healthcare and dermatology, is Owens' largest new add. He
originally purchased 232,200 shares of the company in the fourth
quarter of 2009 at an average price of near $24.50. In the first
quarter of 2012, he added 300,000 shares at an average price of
near $17 per share.
In the last five years, Warner Chilcott's revenue has increased
34.4%, EBITDA 37.7% and free cash flow at 59.4%.
Year to date, its stock increased 44%, including a major surge of
approximately 25% in April after the announcement that the
company is considering a sale to enhance shareholder value. It is
still in preliminary stages and no further developments have been
Owens continued to build his holding of
Boston Scientific (
, a medical device developer, manufacturer and marketer, in the
first quarter. He originally bought 9.2 million shares in the
fourth quarter of 2009 at approximately $9 per share, and had
bought in subsequent quarters - aside from two small sales -
until he owned 36,300,000 shares in the fourth quarter 2011. In
the first quarter 2012, he bought 10.5 million shares at an
average price of near $6, for a total of 46.8 million shares, a
1.3% weighting in his portfolio.
Boston Scientific's stock price has increased 17% year to date
after a significant slide in 2011, helped by second-quarter
earnings per share guidance above analysts' expectations issued
in April. The company's revenue has been falling in the last
three years, from $8.2 billion in 2009 to $7.6 billion in 2011.
In the second quarter, Boston Scientific generated sales of
$1.866 billion and earnings per share of $0.08, above its
The sales declines were seen in its interventional cardiology
segment (down 5% year over year) and its cardiac rhythm
management segment (down 10% year over year). Boston Scientific
Corp. CEO Hank Kucheman told the Ft. Worth Star Tribune that
while sales are lagging, the market for them appears to be
stabilizing, though it has not yet turned around. Other product
categories improved, such as peripheral interventions and
peripheral interventions, which were up 8% each, and endoscopy,
which rose 5%.
The company estimates full-year 2012 sales to be in the range of
$1.85 billion to $1.95 billion and earnings per share to be in a
range of $0.06 to $0.09.
' newly updated portfolio
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to